Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static-preview.hindawi.com/articles/criog/volume-2022/6579715/figures/6579715.fig.001a.svgz" name="6579715.fig.001a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>August 2020</td></tr><tr class="fig-image" id="b"><td><object data="https://static-preview.hindawi.com/articles/criog/volume-2022/6579715/figures/6579715.fig.001b.svgz" name="6579715.fig.001b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>August 2021</td></tr><tr class="fig-image" id="c"><td><object data="https://static-preview.hindawi.com/articles/criog/volume-2022/6579715/figures/6579715.fig.001c.svgz" name="6579715.fig.001c" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(c) </b>August 2020</td></tr><tr class="fig-image" id="d"><td><object data="https://static-preview.hindawi.com/articles/criog/volume-2022/6579715/figures/6579715.fig.001d.svgz" name="6579715.fig.001d" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(d) </b>August 2021</td></tr></table>

<div>Interval decrease in disease burden over one year period of olaparib administration, including hepatic dome lesion from 58x42 mm (a) to 24x18 mm (b); lower right paracolic gutter lesion from 108x66 mm (c) to complete response (d).</div>

Case Reports in Obstetrics and Gynecology

fig1

Figure 1

Figure 1: Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib 